Sarepta Therapeutics, Inc. (BMV:SRPT)

Market Cap	38.79B
Revenue (ttm)	44.27B
Net Income (ttm)	-4.98B
Shares Out	n/a
EPS (ttm)	-50.83
PE Ratio	n/a
Forward PE	11.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24
Average Volume	3,039
Open	375.50
Previous Close	395.00
Day's Range	375.50 - 375.50
52-Week Range	198.74 - 2,501.45
Beta	n/a
RSI	48.62
Earnings Date	Feb 25, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 1,372
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: SRPT

Financial Performance

Financial numbers in USD